This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Jun 27;213(7):1115.

doi: 10.1084/jem.2137insight2.

Combination immunotherapy for cancer

Douglas Fearon¹

Affiliations

PMID: 27353088
PMCID: PMC4925029
DOI: 10.1084/jem.2137insight2

Comment

Combination immunotherapy for cancer

Douglas Fearon. J Exp Med. 2016.

. 2016 Jun 27;213(7):1115.

doi: 10.1084/jem.2137insight2.

Author

Douglas Fearon¹

Affiliation

¹ Cold Spring Harbor Laboratory and Weill Cornell Medicine dfearon@cshl.edu.

PMID: 27353088
PMCID: PMC4925029
DOI: 10.1084/jem.2137insight2

No abstract available

PubMed Disclaimer

Figures

None — Insight from Douglas Fearon

See this image and copyright information in PMC

Comment on

Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.
Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S, Sloan HL, Lai I, Wagener F, Shibuya K, Cao J, Wolchok JD, Greenberg PD, Yee C. Chapuis AG, et al. J Exp Med. 2016 Jun 27;213(7):1133-9. doi: 10.1084/jem.20152021. Epub 2016 May 30. J Exp Med. 2016. PMID: 27242164 Free PMC article. Clinical Trial.

References

1. Chapuis, A.G., et al. . 2016. J. Exp. Med. 10.1084/jem.20152021 - DOI - PubMed
1. Postow, M.A., et al. . 2015. N. Engl. J. Med. 372:2006–2017. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations